Pier Paolo Claudio
Professor
Department:
SOM-Pharmacology/Toxicology
Email:
pclaudio@umc.edu
Work Phone:
(601) 984-1600
Biography
Dr. Pier Paolo Claudio is a Professor of Pharmacology and Toxicology at the University of Mississippi Medical Center (UMMC), where he also holds appointments in Radiation Oncology and Maxillofacial Surgery. He serves on the Cancer Institute Research Advisory Committee and chairs the Oversight Subcommittee of the Intellectual Property Committee. Dr. Claudio earned his MD and doctoral degrees *summa cum laude* from the University of Naples Frederick II. His research focuses on innovative cancer therapies, including ultrasound-guided gene delivery and the ChemoID drug response assay, both protected by multiple U.S. and international patents. He has secured over $21 million in research funding and published nearly 200 peer-reviewed papers. His ChemoID assay has been validated in multi-institutional clinical trials and recently received FDA Breakthrough Device Designation for glioblastoma. Dr. Claudio bridges basic and clinical cancer research across UMMC and the University of Mississippi, advancing precision oncology. He has taught cancer biology, translational medicine, and radiobiology to medical, graduate, and resident students since 1998. He is Editor-in-Chief of the *International Journal of Translational Medicine* and serves on several editorial boards. His career reflects a dedication to translating laboratory discoveries into meaningful clinical applications.
Education
| Massachusetts Institute of Technology, Certification, Drugs and Medical Device Development | 2023 |
| University of Naples "Federico II", PhD, Surgery | 1994 |
| University of Naples "Federico II", Residency, Surgery | 1994 |
| University of Naples "Federico II", MD, Medicine | 1989 |
Specialty Certification Licensure
| Certification, Strategies for Drugs and Device Development, MIT | 06/2023 - Present |
Current Positions
| Professor, School of Medicine, Department of Pharmacology / Toxicology | 2023 - Present |
| The University of Mississippi Medical Center Jackson, Mississippi 39216 | |
Academic Appointments or Other Previous Appointments
| Professor, University of Mississippi, School of Pharmacy, Department of BioMolecularSciences | 07/2015 - 2023 |
| Director, Marshall University, School of Medicine, Department of Translational Genomics Research Institute (TGRI) | 2009 - 12/2015 |
| Associate Professor, Marshall University, School of Medicine, Department of Biochemistry and Microbiology | 2006 - 12/2015 |
| Director, Temple University, School of Medicine, Department of Molecular Therapeutics Program | 2002 - 12/2006 |
| Associate Professor, Temple University, School of Medicine, Department of Biology | 2002 - 12/2006 |
| Associate Professor, Thomas Jefferson University, School of Medicine, Department of Pathology | 2000 - 12/2002 |
| Assistant Professor, University of Naples Federico II, School of Medicine, Department of Head & Neck Surgery | 1998 - 12/2004 |
| Assistant Professor, Thomas Jefferson University, School of Medicine, Department of Pathology | 1998 - 12/2000 |
| Instructor, Thomas Jefferson University, School of Medicine, Department of Pathology | 1996 - 12/1998 |
Sponsored Program Funding
| Extramural, Functional Precision Medicine Assay for Brain Metastasis, DOD | 01/2026 - 12/2030 |
| Extramural, In vitro Production of Red Blood Cells for Transfusion Readiness, DOD | 01/2026 - 12/2030 |
| Extramural, In vitro Production of Red Blood Cells for Transfusion Readiness, NIH | 12/2025 - 01/2029 |
| Intramural, Personalized Functional Medicine Testing for Unresectable Glioblastoma with Unmethylated MGMT Promoter, CCRI Catalyst Award Fund | 08/2025 - 07/2026 |
| Extramural, Antibody delivery for immunotherapy, Vesselon | 01/2025 - 12/2026 |
| Intramural, Small scale Red Blood Cells Production and Characterization, MCCTR | 01/2024 - 12/2025 |
| Extramural, Preclinical study on a new paclitaxel formulation (ART207), in Cancer Stem Cells (CSCs) and Bulk of Tumor Cells from patient-derived cell lines of ovarian, breast colon, pancreas, and lung cancer origin., Romolus Therapeutics | 08/2023 - 12/2023 |
| Extramural, Preclinical study on a new paclitaxel formulation (ART207), in Cancer Stem Cells (CSCs) and Bulk of Tumor Cells from patient-derived cell lines of ovarian, breast colon, pancreas, and lung cancer origin., Romolus Therapeutics | 08/2023 - 07/2024 |
| Extramural, Improving AAV delivery for immunotherapy, Vesselon | 01/2022 - 12/2023 |
| Intramural, Ultrasound targeted microbubble destruction for anticancer gene delivery., UMMC Intramural grant | 01/2021 - 12/2022 |
| Intramural, Sensitizing Effects of Benzyl Isothiocyanate (BITC) on standard treatment for Head and Neck Cancer, CCTS UM/UMMC Preclinical/Translational Unit Award | 06/2020 - 06/2021 |
| Extramural, Gene therapy is a new approach to treating prostate cancer (PC)., Brown Foundation | 01/2020 - 12/2022 |
| Extramural, Standard Chemotherapy versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer. NCT03949283 | 01/2019 - 12/2024 |
| Extramural, Standard chemotherapy versus chemotherapy chosen by cancer stem cell chemosensitivity testing in the management of patients with recurrent Glioblastoma Multiforme (GBM). NCT03632135 | 01/2017 - 12/2023 |
| Extramural, Preclinical study on a new paclitaxel formulation (ART207), in Cancer Stem Cells (CSCs) and Bulk of Tumor Cells from patient-derived cell lines of ovarian, breast colon, pancreas, and lung cancer origin., Romolus Therapeutics | 01/2017 - 12/2023 |
| Intramural, Ultrasound targeted microbubble destruction for anticancer gene delivery, UMMC Intramural Grant | 01/2016 - 12/2017 |
| Extramural, Chemotherapy resistance and sensitivity testing in lung tumors., CTSA MARSHALL/UK | 12/2012 - 01/2014 |
| Intramural, Chemotherapy resistance and sensitivity testing in tumors of the central nervous system, Dept Neuroscience Marshall University | 12/2012 - 01/2014 |
| Extramural, Identifying the Role of P53 and PRB Regulated Protein RGS16 in Osteosarcoma Proliferation and Chemoresistance., NASA | 07/2012 - 06/2013 |
| Intramural, Chemotherapy resistance and sensitivity testing in tumors of the central nervous system, Marshall Univeristy Translational Award | 07/2012 - 06/2014 |
| Extramural, WV Cancer Genomics Network | 07/2012 - 06/2017 |
| Extramural, Characterization of HUS1B: a novel player in the p53/pRb tumor suppressor pathways, NASA | 07/2011 - 06/2012 |
| Extramural, Chemosensitization of Non-Small Lung Cancer Stem Cells with Isothiocyanates., NASA | 07/2011 - 06/2012 |
| Extramural, Exploring BITC Ability to Enhance Chemosensitivity and Reduce the Metastatic Potential of Head and Neck Cancer Cells., NASA | 07/2011 - 06/2012 |
| Extramural, Dry beans and colon cancer stem-like cells, from mechanisms to therapy, Northern Bean Growers Association | 03/2010 - 03/2011 |
| Extramural, Ultrasound-guided gene delivery in pancreatic cancer., NIH | 08/2009 - 07/2013 |
| Extramural, Ultrasound-guided site-specific gene delivery in prostate cancer, NIH | 01/2009 - 03/2013 |
| Intramural, Microgravity sensitization to chemotherapy of multi-drug resistant cancer cells, CDDC | 01/2006 - 12/2008 |
| Extramural, Ultrasound enhancement of viral-mediated gene transfer following systemic administration, WW Smith Foundation | 01/2004 - 12/2006 |
| Extramural, pRb2/p130 from the mechanism to therapy., NIH | 01/2003 - 12/2008 |
| Extramural, Role of the RB Family in JC virus-induced glioblastomas., NIH | 01/2002 - 12/2006 |
Publications
Journal Article | |
| Diana Polania Villanueva, Charles Ingraham, Annamarie Macaluso, Cecilia Vittori, Jean- Jacques Hunter, Monika Rak, Pier Paolo Claudio, Mahomed A. Ibrahim, Luis Del Valle, Francesca Peruzzi, Branko S Jursic, and Krzysztof Reiss. Antiglioblastoma Drug Candidates Targeting Mitochondrial Respiration. Journal Cell Physiology (in press 2025) | 2025 |
| Spirito F, Claudio PP, Howard CM, Valluri J, Denning KL, Muzio LL, Cortese A. A New and Effective Procedure for Advanced Oral Cancer Therapy: The Potential of a Cancer Stem Cell Assay in Guiding Chemotherapy. Spirito F, Claudio PP, Howard CM, Valluri J, Denning KL, Muzio LL, Cortese A. A New and Effective Procedure for Advanced Oral Cancer Therapy: The Potential of a Cancer Stem Cell Assay in Guiding Chemotherapy. Transl Med UniSa. 2023 Dec 8;25(1):16-27. doi: 10.37825/2239-9747.1042. PMID: 38143509 | 2023 |
| Isahia A. Edwards, Flavia De Carlo, Juliana Sitta, William Varner, Candace M. Howard, Pier Paolo Claudio. Ultrasound Enhanced Targeted Therapy in Breast Cancer. Isahia A. Edwards, Flavia De Carlo, Juliana Sitta, William Varner, Candace M. Howard, Pier Paolo Claudio. Ultrasound Enhanced Targeted Therapy in Breast Cancer. Int. J. Mol. Sci. 2023, 24(6), 5474; PMID: 36982548 | 2023 |
| Cortese, S. Catalano, C.M. Howard, P.P. Claudio. New minimally invasive intraoral procedure for condylar fractures: clinical case and considerations on current techniques. Cortese, S. Catalano, C.M. Howard, P.P. Claudio. New minimally invasive intraoral procedure for condylar fractures: clinical case and considerations on current techniques. Journal of Maxillofacial Surgery, 2022 May 1;33(3):e245-e247. doi: 10.1097/SCS.0000000000008028. PMID: 34406154 | 2022 |
| Cortese A, Catalano S, Rauso R, Claudio PP. Condylar Fractures: Multistep Surgical Planning by Mini-Invasive Approach, Patient Series. Cortese A, Catalano S, Rauso R, Claudio PP. Condylar Fractures: Multistep Surgical Planning by Mini-Invasive Approach, Patient Series. J Craniofac Surg. 2022 Mar 11. doi: 10.1097/SCS.0000000000008643. Online ahead of print. PMID: 35275857 | 2022 |
| Candace M. Howard, Stephen Bush II, Nadim Bou Zgheib, Antonio Cortese, Antonio Mollo, Jagan Valluri, and Pier Paolo Claudio. Cancer Stem Cell Assay for the treatment of Recurrent Ovarian Cancer. Candace M. Howard, Stephen Bush II, Nadim Bou Zgheib, Antonio Cortese, Antonio Mollo, Jagan Valluri, and Pier Paolo Claudio. Cancer Stem Cell Assay for the treatment of Recurrent Ovarian Cancer. J Stem Cell Res Dev Ther 2021, 7: 076. DOI: 10.24966/SRDT-2060/100076 | 2021 |
| Timothy G. DeEulis, Candace M. Howard, Jagan Valluri, and Pier Paolo Claudio. Efficacy of ChemoID guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: Case Study. Translational Medicine Reports, vol 1: 6701, 70-75, 2017. Timothy G. DeEulis, Candace M. Howard, Jagan Valluri, and Pier Paolo Claudio. Efficacy of ChemoID guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: Case Study. Translational Medicine Reports, vol 1: 6701, 70-75, 2017. | 2017 |
| Cortese A., D’Alessio G., Brongo S., Gargiulo M., Claudio P.P. Management of zygomatic fractures in young patients: Technical modifications for aesthetic and functional results. Cortese A., D’Alessio G., Brongo S., Gargiulo M., Claudio P.P. Management of zygomatic fractures in young patients: Technical modifications for aesthetic and functional results. J. Craniofacial Surgery 2016; Nov 27 (8): 2073-2077. PMID 28005755 | |
| Cortese A, D’Alessio G, Brongo S, Amato M, Sarno MR, Claudio PP. New Techniques in Relation to New Concepts of the Aesthetic of the Face: Technical Considerations and Aesthetic Evaluation. Cortese A, D’Alessio G, Brongo S, Amato M, Sarno MR, Claudio PP. New Techniques in Relation to New Concepts of the Aesthetic of the Face: Technical Considerations and Aesthetic Evaluation. J Craniofac Surg 2016, Oct;27(7):e693-e695. PMID: 27564069 | |
| Steve J. Bannister, Amir E. Wahba, Mahesh Kumar Gundluru, Igor Nikoulin, Douglas L. Rodenburg, Michael L. Coen, David A. Lewis, Patrice Penfornis, Pier Paolo Claudio, James D. McChesney. TumorSelect® Technology Enhancing the Safety and Efficacy of Cancer Chemotherapy. Steve J. Bannister, Amir E. Wahba, Mahesh Kumar Gundluru, Igor Nikoulin, Douglas L. Rodenburg, Michael L. Coen, David A. Lewis, Patrice Penfornis, Pier Paolo Claudio, James D. McChesney. TumorSelect® Technology Enhancing the Safety and Efficacy of Cancer Chemotherapy. BMC Cancer. DOI 10.21203/rs.3.rs-701601/v1 | |
Book Chapter | |
| Rounak Nande and Pier Paolo Claudio Ultrasound Contrast Agents in Cancer Therapy. Rounak Nande and Pier Paolo Claudio. (2014) Ultrasound Contrast Agents in Cancer Therapy. In P.P. Claudio & V. Vogiatzi (Eds.), Cutting edge therapies for cancer in the 21st century. Oak Park, IL: Bentham Science Publishers Ltd. | 2014 |
| Wolf, M.A. and P.P. Claudio Isothiocyanates target carcinogenesis during tumor initiation, promotion, and progression Wolf, M.A. and P.P. Claudio (2012). Isothiocyanates target carcinogenesis during tumor initiation, promotion, and progression/Article. In P.P. Claudio & R.M. Niles (Eds.), Nutrition and Cancer: From Epidemiology to Biology (p79-86). Oak Park, IL: Bentham Science Publishers Ltd. | 2012 |
| Paraskevi Vogiatzi, Maria Irene Scarano, and Pier Paolo Claudio Epigenetic Targets and Drug Development. In Cancer Epigenetics: Paraskevi Vogiatzi, Maria Irene Scarano, and Pier Paolo Claudio. Chapter 14. Epigenetic Targets and Drug Development. In Cancer Epigenetics: Biomolecular Therapeutics in Human Cancer. John Wiley and Sons Ltd, March 2012, Pages: 436. | 2012 |
| Claudio P.P. and Vogiatzi P. Distinct roles of the pocket proteins in the control of cell cycle. Claudio P.P. and Vogiatzi P. (2010): Distinct roles of the pocket proteins in the control of cell cycle. In: Signal Transduction: Pathways, Mechanisms, and Diseases. Springer Ed. 353-374. | 2010 |
| Claudio P.P. and Denning D. Nasopharyngeal carcinoma. In Cancer Research, an encyclopedic reference book. Claudio P.P. and Denning D. (2007): Nasopharyngeal carcinoma. In Cancer Research, an encyclopedic reference book. Springer Ed. 615-618. | 2007 |
| Alessandro Bovicelli, Pier Paolo Claudio and Antonio Giordano. The multidisciplinary therapeutic approach to gynecological cancer in the new millennium. Molecular Pathology of Gynecological Cancer. Part VII: The multidisciplinary therapeutic approach to gynecological cancer in the new millennium. Chapter 13: The Holistic Approach to Female Cancer Patients. Alessandro Bovicelli, Pier Paolo Claudio and Antonio Giordano. Humana Press. | 2007 |
| Pier Paolo Claudio, Antonio Giordano Angiogenesis and cancer. Practical Medical Oncology. Pier Paolo Claudio, Antonio Giordano. Angiogenesis and cancer. Practical Medical Oncology. Ed M. Lopez. Second Edition 2005. | 2005 |
| Tiziana Tonini, Pier Paolo Claudio, Antonio Giordano and Gaetano Romano. Retroviral and lentiviral vector titration by the analysis of the activity of viral reverse transcriptase. Tiziana Tonini, Pier Paolo Claudio, Antonio Giordano and Gaetano Romano. (2004): in Methods in Molecular Biology. Cell cycle control and dysregulation protocols. Part IV RETROVIRIDAE-BASED VECTORS: PROTOCOLS FOR LENTIVIRAL – AND RETROVIRAL-MEDIATED GENE TRANSFER TO ENGINEER CELL CULTURE SYSTEMS. Retroviral and lentiviral vector titration by the analysis of the activity of viral reverse transcriptase. Humana Press. Chapter 20. | 2004 |
| Tiziana Tonini, Pier Paolo Claudio, Antonio Giordano and Gaetano Romano. Determination of functional viral titer by drug-resistance colony assay, expression, expression of green fluorescent protein, and beta-galactosidase staining Tiziana Tonini, Pier Paolo Claudio, Antonio Giordano and Gaetano Romano. (2004): in Methods in Molecular Biology. Cell cycle control and dysregulation protocols. Part IV RETROVIRIDAE-BASED VECTORS: PROTOCOLS FOR LENTIVIRAL – AND RETROVIRAL-MEDIATED GENE TRANSFER TO ENGINEER CELL CULTURE SYSTEMS. Determination of functional viral titer by drug-resistance colony assay, expression, expression of green fluorescent protein, and beta-galactosidase staining. Humana Press, Chapter 19. | 2004 |
| Tiziana Tonini, Pier Paolo Claudio, Antonio Giordano and Gaetano Romano. Transient production of retroviral-and lentiviral-based vectors for the transduction of mammalian cells. Tiziana Tonini, Pier Paolo Claudio, Antonio Giordano and Gaetano Romano. (2004): in Methods in Molecular Biology. Cell cycle control and dysregulation protocols. Part IV RETROVIRIDAE-BASED VECTORS: PROTOCOLS FOR LENTIVIRAL – AND RETROVIRAL-MEDIATED GENE TRANSFER TO ENGINEER CELL CULTURE SYSTEMS. Transient production of retroviral-and lentiviral-based vectors for the transduction of mammalian cells. Humana Press, Chapter 18. | 2004 |
| Claudio, F., Claudio, P.P. I tumori della lingua. Claudio, F., Claudio, P.P. (2003): I tumori della lingua. Capitolo 36. In Mazzeo, F., Forestieri, P. Ed. Piccin Nuova Libraria Padova. Trattato di Chirurgia Oncologica. Vol 2, pag. 39.1-39.42. | 2003 |
| Montella, M., Gallipoli, A., Lorusso, A., Creazzola, S., Claudio, P.P., D’Errico, G. L’organizzazione della lotta contro i tumori Montella, M., Gallipoli, A., Lorusso, A., Creazzola, S., Claudio, P.P., D’Errico, G. (2003): L’organizzazione della lotta contro i tumori. Capitolo 36. In Mazzeo, F., Forestieri, P. Ed. Piccin Nuova Libraria Padova. Trattato di Chirurgia Oncologica. Vol 1, pag. 36.1-36.23. | 2003 |
| Claudio PP, Giordano A. Preparation of retroviral vectors for cell cycle-targeted gene therapy of lung cancer. Claudio PP, Giordano A. (2003): Preparation of retroviral vectors for cell cycle-targeted gene therapy of lung cancer. In Barbara Driscoll (Ed.) Lung Cancer, volume II, Diagnostic and therapeutic methods and reviews. Methods Mol Med. Humana Press. 75: 591-605. | 2003 |
| Claudio P. P., Giordano A. RB1 and RB2. Claudio P. P., Giordano A. (2000): RB1 and RB2. In Pass H.I., Mitchell J.B., Johnson D.H., Turrisi A.T., Minna J.D. (Ed.) Lung Cancer: Principles and Practice. Lippincott Williams & Wilkins. 7: 133-155 | 2000 |
| Howard C.M., Claudio P.P., Carbone M., Giordano A. SV40 and Human Cancer. Howard C.M., Claudio P.P., Carbone M., Giordano A. (1998): SV40 and Human Cancer. in Samuels, S.W. and Upton, A.C. Genes, Cancer and Ethics In the Work Environment. OEM Press, Beverly, MA. 167-174. | 1998 |
| De Luca A., Baldi A., Claudio P.P., Howard C.M., Campisi S., Giordano A., Condorelli G. The retinoblastoma gene and its role in cancer and differentiation. De Luca A., Baldi A., Claudio P.P., Howard C.M., Campisi S., Giordano A., Condorelli G. (1995): The retinoblastoma gene and its role in cancer and differentiation. In Future Trends in Endocrinology. Ares-Serono Symposia Series-Frontiers in Endocrinology 14: 197-206. | 1995 |
Book | |
| Claudio P.P., Vogiatzi, V., Editors. “Cutting edge therapies for cancer in the 21st century”. Claudio P.P., Vogiatzi, V., Editors. “Cutting edge therapies for cancer in the 21st century”. Bentham, May 2014. eISBN:978-1-60805-880-8, 2014 ISBN:978-1-60805-881-5. | 2014 |
| Claudio, P.P., Niles, R.M., Editors. “Nutrition and Cancer, from Epidemiology to Biology”. Claudio, P.P., Niles, R.M., Editors. “Nutrition and Cancer, from Epidemiology to Biology”. Bentham, August 2012. DOI: 10.2174/97816080544731120101 eISBN: 978-1-60805-447-3, 2012 ISBN: 978-1-60805-506-7 | 2012 |
| Califano L., Claudio P.P. Parotid tumors. Califano L., Claudio P.P. (1995): Parotid tumors. Ed. Scientifiche Italiane. Napoli, 1-148 | 1995 |
| Claudio P.P., Savastano G. Cutaneous tumors of the face. Reconstructive surgery after ablation. Claudio P.P., Savastano G. (1992): Cutaneous tumors of the face. Reconstructive surgery after ablation. Ed. Scientifiche Italiane. Napoli, 1 - 160. | 1992 |
Editorial Commentary | |
| Candace M. Howard, Jagan Valluri, and Pier Paolo Claudio. Functional drug response assay for cancer stem cells in the era of precision medicine. Candace M. Howard, Jagan Valluri, and Pier Paolo Claudio. Functional drug response assay for cancer stem cells in the era of precision medicine. Translational Medicine Reports (Invited Editorial), vol 1 (1), 2017. DOI: http://dx.doi.org/10.4081/tmr.6421 . | 2017 |
| Candace M. Howard, Jagan Valluri, and Pier Paolo Claudio. T The Future of Precision Medicine in Oncology: Targeting Cancer Stem Cells. Candace M. Howard, Jagan Valluri, and Pier Paolo Claudio. The Future of Precision Medicine in Oncology: Targeting Cancer Stem Cells. Clinics in Oncology (Invited Editorial), 2017, Vol. 2, Article 1187. | 2017 |
Presentations
| National and International Invited Seminars/Lectures, Cancer Stem Cells to Advance Functional Medicine in the Era of Precision Oncology, SICMF, Naples, Italy | 06/2025 |
| National and International Invited Seminars/Lectures, Using Cancer Stem Cells to Advance Functional Medicine in the Era of Precision Oncology. Pier Paolo Claudio. AACR Meeting 2025, March 10 - 13. Oral presentation to the Plenary Session at AACR 2025, Boston., AACR, Boston | 03/2025 |
| National and International Invited Seminars/Lectures, Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial. Oral presentation to the Gynecology Oncology Plenary Session at ASCO 2024, Chicago, IL., ASCO, Chicago | 06/2024 |
| National and International Invited Seminars/Lectures, Precision Medicine Trial for Newly Diagnosed High-Grade Gliomas., NRG Oncology, Philadelphia, PA | 07/2023 |
| National and International Invited Seminars/Lectures, Precision medicine through cancer stem cells., University Federico II of Naples, Naples, Italy | 03/2023 |
| National and International Invited Seminars/Lectures, Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade gliomas (NCT03632135), SNO/ASCO CNS Clinical Trial and Brain Metastasis Conference, Toronto, Canada | 08/2022 |
| National and International Invited Seminars/Lectures, Recurrent Anaplastic Green Ependymoma Supplement Study (RAGES study), BRAIN TUMOR CENTER NEURO-ONCOLOGY CLINICAL RESEARCH DAY Seattle, Seattle | 10/2021 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: Precision medicine through a functional cancer stem cells assay and the potential of green chemotherapy to improve patients’ outcomes, Cancer Grand Rounds, Seattle Science Foundation., Seattle | 08/2021 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: ChemoID - Cancer Stem Cell Drug Response Assay to Personalize Cancer Management., Temple University - FELS INSTITUTE, Philadelphia, PA | 04/2019 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: ChemoID - Cancer Stem Cell Drug Response Assay to Personalize Cancer Management., Louisiana Sate University, New Orleans | 04/2019 |
| State/Local Invited Seminars/Lectures, CANCER GRAND ROUNDS: ChemoID - Use of Cancer Stem Cell Drug Response Assay to Improve the Outcome of Cancer Patients, UMMC, Jackson MS | 03/2019 |
| National and International Invited Seminars/Lectures, Prospective Analysis of Chemo-predictive Assay to Target Cancer Stem Cells in Glioblastoma Patients, Cancer Stem Cell Meeting, Austria | 12/2018 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: Personalizing treatment in the management of cancer. School of Medicine, University of Salerno, Italy, Salerno, Italy | 06/2018 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: ChemoID- personalizing treatment in the management of newly diagnosed and recurrent glioblastoma, PennState University, Hershey, PA | 05/2018 |
| National and International Invited Seminars/Lectures, Prospective Analysis of Chemo-predictive Assay to Target Cancer Stem Cells in Glioblastoma Patients., Society of NeuroOncology Annual Meeting, New Orleans | 04/2018 |
| State/Local Invited Seminars/Lectures, Personalizing treatment in the management of cancer., UMMC-School of Dentistry, Jackson, MS | 03/2018 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: ChemoID- personalizing treatment in the management of newly diagnosed and recurrent glioblastoma, University of CIncinnati, Cincinnati, OH | 03/2018 |
| National and International Invited Seminars/Lectures, Efficacy of in vitro ChemoID guided drug selection for palliative chemotherapy in advanced recurrent ovarian adenocarcinoma: a case study., MD Anderson, Houston | 10/2017 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: Prospective Analysis of Chemo-predictive Assay to Target Cancer Stem Cells in Glioblastoma Patients, Toledo University, Toledo, OH | 06/2017 |
| National and International Invited Seminars/Lectures, ChemoID a Chemo-predictive Assay to Target Cancer Stem Cells in Head and Neck Cancer Patients, International Meeting INTHEMA, Naples, Italy | 03/2017 |
| National and International Invited Seminars/Lectures, ChemoID is a Chemo-predictive Assay to Target Cancer Stem Cells in Cancer Patients., Italian Institute of Technology (ITT), Genova, Italy | 03/2017 |
| National and International Invited Seminars/Lectures, Prospective Analysis of Chemo-predictive Assay to Target Cancer Stem Cells in Glioblastoma Patients, International Cancer Study & Therapy Conference, Baltimore | 02/2017 |
| Regional Invited Seminars/Lectures, Prospective Analysis of Chemo-predictive Assay to Target Cancer Stem Cells in Glioblastoma., Southern Regional Meeting, New Orleans | 02/2017 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: Chemosensitivity assay for targeting cancer stem-like cells in Glioblastoma., CAMC Hospital, Charleston, WV | 12/2016 |
| National and International Invited Seminars/Lectures, Prospective Analysis of Chemo-Predictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients, Cleveland Clinic, Cancer Stem Cell Conference, Cleveland, OH | 09/2016 |
| National and International Invited Seminars/Lectures, Development of Innate Immune Enhancing Botanicals and Identification of Tumor-Specific Chemotherapy/Botanical Combinations, University Federico II of Naples, Naples, Italy | 05/2016 |
| State/Local Invited Seminars/Lectures, NEURO-ONCOLOGY GRAND ROUNDS: Chemosensitivity assay for targeting cancer stem-like cells in malignant solid tumors., UMMC Neuro-Oncology, Jackson, MS | 04/2016 |
| National and International Invited Seminars/Lectures, Chemosensitivity assay for targeting cancer stem-like cells in malignant solid tumors of the head and neck, 23rd International meeting of Head and Neck Academicians, Naples, Italy | 04/2016 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: Chemosensitivity assay for targeting cancer stem-like cells in Glioblastoma., West Virginia University Hospital, Morgantown, WV | 02/2016 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: Chemosensitivity assay for targeting cancer stem-like cells in Glioblastoma, West Virginia University Hospital, Charleston, WV | 02/2016 |
| National and International Invited Seminars/Lectures, CANCER GRAND ROUNDS: Chemosensitivity assay for targeting cancer stem-like cells in malignant solid tumors., University of Cincinnati, Comprehensive Cancer Center and University Hospitals, Cincinnati OH | 09/2014 |
| National and International Invited Seminars/Lectures, Chemosensitivity assay for targeting cancer stem-like cells in malignant solid tumors., OleMiss, Oxford, MS | 09/2014 |
Honors, Awards, and Recognition
| https://www.uc.edu/news/articles/2025/04/chemoid-test-leads-to-better-outcomes-in-platinum-resistant-ovarian-cancer.html, Press Release | 2025 |
| https://www.news-medical.net/news/20250404/ChemoID-test-leads-to-better-outcomes-in-platinum-resistant-ovarian-cancer.aspx, Press Release | 2025 |
| https://www.insideprecisionmedicine.com/topics/oncology/brain-cancer/stem-cell-based-treatment-selection-assay-led-to-improved-recurrent-glioblastoma-survival/, Press Release | 2025 |
| https://www.stemcellsciencenews.com/newsletter/206290/, Press Release | 2025 |
| Breakthrough Device Designation (BDD) status is awarded to ChemoID Assay by the Food and Drug Administration (FDA) to diagnose and treat unmethylated MGMT promoter glioblastoma, FDA | 2024 |
| https://www.businesswire.com/news/home/20190917005129/en/Immuno-oncology-Innovator-Vesselon-Expands-Portfolio-Patented-Technology, Press Release | 2024 |
| https://www.uc.edu/news/articles/2023/05/study-finds-chemoid-platform-predicted-treatments-lead-to-longer-survival.html, Press Release | 2024 |
| https://www.news-medical.net/news/20230505/Cancer-stem-cell-test-can-lead-to-increased-survival-for-patients-with-glioblastoma.aspx, Press Release | 2024 |
| https://www.news-medical.net/news/20230505/Cancer-stem-cell-test-can-lead-to-increased-survival-for-patients-with-glioblastoma.aspx, Press Release | 2024 |
| https://www.psychreg.org/chemoid-platform-predicted-treatments-lead-longer-survival-glioblastoma-patients/, Perss Release | 2024 |
| https://www.m3india.in/contents/clinical_news/study-chemoid-platform-predicted-treatments-lead-to-longer-survival-for-glioblastoma?feed=97390114, Pres Release | 2024 |
| https://www.youtube.com/watch?v=YaD8-Y6QtB0, Press Release | 2024 |
| https://www.medimagazine.it/glioblastoma-piattaforma-chemoid-aumenta-la-sopravvivenza/, Press Release | 2024 |
| https://tvfcommunications.com/blog/cancer-treatment-is-getting-personal/, Press Release | 2024 |
| https://clpmag.com/disease-states/cancer/unknown-other-cancer/chemoid-test-can-lead-to-longer-glioblastoma-patient-survival/, Press Release | 2024 |
| https://www.labmedica.com/immunology/articles/294797119/cancer-stem-cell-test-improves-survival-of-patients-with-deadly-brain-tumor.html, Press Release | 2024 |
| https://ichgcp.net/clinical-trials-registry/NCT03949283, Press Release | 2024 |
| https://www.wvgazettemail.com/news/health/new-technology-develops-better-personalized-cancer-treatments/article_9c2a1775-c04a-5a02-a53c-2396fb8d8f1c.html, Press Release | 2024 |
| https://www.thehealthsite.com/diseases-conditions/cancer/heath-tech-4-innovative-technologies-that-will-change-cancer-treatment-734440/, Press Release | 2024 |
| https://www.tgh.org/institutes-and-services/cancer-institute/neurological-cancer-program, Press Release | 2023 |
| https://www.uc.edu/news/articles/2022/05/vjoncology--chemoid-trial-shows-increased-survival.html, Press Release | 2022 |
| https://www.medscape.com/viewarticle/972276, Press Release | 2022 |
| https://www.mdedge.com/hematology-oncology/article/253824/cns/brain-cancer/assay-guided-chemo-recurrent-glioma-linked, Press Release | 2022 |
| https://www.cancertherapyadvisor.com/home/news/conference-coverage/american-association-for-cancer-research-aacr/aacr-2022/high-grade-glioma-assay-guided-therapy-improves-survival/, Press Release | 2022 |
| https://www.pvhomed.com/new-technology-is-making-a-difference-in-the-fight-against-cancer/, Press Release | 2022 |
| https://www.uc.edu/news/articles/2022/05/vjoncology--chemoid-trial-shows-increased-survival.html, Press Release | 2022 |
| https://www.thehealthsite.com/diseases-conditions/cancer/heath-tech-4-innovative-technologies-that-will-change-cancer-treatment-734440/, Press Release | 2022 |
| https://www.ahn.org/services/cancer/types/brain/treatment.html, Press Release | 2021 |
| www.uc.edu/news/articles/2019/01/n2062227.html, Press Release | 2019 |
| https://www.umc.edu/news/News_Articles/2017/February/Researcher-s-goal--Find-the-best-chemo-for-each-patient.html, Press Release | 2017 |
| Poster Communication Award, UMMC - The Center for Bioethics and Medical Humanities & the Rowland Medical Library | 2016 |
| European Patent Serial Number 09721750.9 “Method for Stem Cell Production and Therapy”, issued on April 29, 2016., European Patent Office | 2016 |
| U.S. Patent Serial Number: 9,316,632: “Methods of screening chemotherapeutic agents and treating cancer”, issued Feb 9, 2016., USPTO | 2016 |
| https://nuemd.com/news/2016/09/22/3-new-technologies-field-cancer-treatment, Press Release | 2016 |
| ChemoID trademark, allowed in 2016, USPTO | 2016 |
| U.S. Patent Serial Number: 8,993,231: “Methods for stem cells production and therapy”, issued March 31, 2015., USPTO | 2015 |
| U.S. Patent Serial Number 8,454,937: “Method and composition for the site-selective delivery using viruses encapsulated in microbubbles”, issued on June 4, 2013., USPTO | 2013 |
| Stem Cell Research Award, Lion’s Club Fondi, Italy | 2008 |
| BioMedical Sciences Award, International Award “Sebetia-Ter” | 2007 |
| Outstanding Achievements in Gene Therapy Award, Rotary Club – Napoli | 2004 |
| U.S. Patent Serial Number 10/250,805: “Method for quantification of recombinant viruses”, issued on February 12, 2004., USPTO | 2004 |
| U.S. Patent Serial Number 6596698. “Methods of inhibiting smooth muscle cell proliferation and preventing restenosis with a vector expressing RB2/p130”, issued on July 22, 2003., USPTO | 2003 |
| Who’s Who in Science and Engineering, Who’s Who in Science and Engineering | 2002 |
| Outstanding achievement in cancer research., Lions Club Napoli-Mergellina | 1999 |
| Research Fellowship Award, Associazione Leonardo di Capua”, Napoli, Italy | 1999 |
| Research Fellowship from the “Associazione Leonardo di Capua”, Napoli, Italy, for a research project on Nasopharyngeal Cancer., Associazione Leonardo di Capua | 1999 |
| Research Fellowship Award, American-Italian Cancer Foundation, New York, USA. | 1995 |
| Research Fellowship from the American-Italian Cancer Foundation, New York, USA., American-Italian Cancer Foundation | 1995 |
| Summa cum Laude, University Federico II of Naples, Italy | 1994 |
| Research Fellowship Award, Lega Nazionale Lotta Contro I Tumori” of the National Institute of Tumor “Fondazione Senatore Pascale,” Naples, Italy. | 1994 |
| Research Fellowship from “Lega Nazionale Lotta Contro I Tumori” of the National Institute of Tumor “Fondazione Senatore Pascale,” Naples, Italy., National Cancer Institute, Italy | 1994 |
| Summa cum Laude, University Federico II of Naples, Italy | 1989 |
| Fellowship Training Award, Head & Neck Surgery at the University of Naples “Federico II,” Italy. | 1989 |
| Training Fellowship awarded for training in Head & Neck Surgery at the University of Naples “Federico II,” Italy., University of Naples “Federico II,” Italy. | 1989 |
| II Edition of the National Award for Young Researchers “A. Schweitzer”, Italy., II Edition of the National Award for Young Researchers “A. Schweitzer”, Italy | 1987 |
Professional Membership and Service
| International non-transfusional Hemocomponents Academy (intHEMA)., Officer, Vice President | 2023 - Present |
| Society of Neuro-Oncology (SNO), Member | 2019 - Present |
| International non-transfusional Hemocomponents Academy (intHEMA)., Officer, Vice President | 2016 - Present |
| International non-transfusional Hemocomponents Academy (intHEMA)., Founder Member | 2015 - Present |
| Mississippi Academy of Sciences, Member | 2015 - Present |
| American Association Clinical Oncology (ASCO)., Member | 2011 - Present |
| American Society for Gene & Cell Therapy (ASGCT)., Member | 2009 - Present |
| Head & Neck Optical Diagnostics Society (HNODS)., Member | 2009 - Present |
| American Association for Cancer Research (AACR), Member | 2000 - Present |
| European Association for Cranio-Maxillo-Facial Surgery (E.A.C.M.F.), Member | 1991 - Present |
| Societa’ italiana dei Giovani Chirurghi (S.P.I.G.C.), Member | 1990 - Present |
| Societa' Italiana di Chirurgia Maxillo Facciale (S.I.C.M.F.), Member | 1990 - Present |
Committee Service
| CCRI membership committee, Member | 2025 - Present |
| CCRI Experimental Therapeutics Program, Member | 2025 - Present |
| Dept. of Pharmacology hiring committee, Chair | 2024 - Present |
| Intellectual Property Executive Committee, Member | 2021 - Present |
| Intellectual Property Oversight Committee, Chair | 2021 - Present |
| CCRI Experimental Therapeutics Program, Member | 2018 - 2023 |
| Scientific Leadership Council, University of Mississippi Medical Center, Cancer Center & Research Institute., Member | 2017 - 2023 |
| SCHOOL OF DENTISTRY-RESEARCH ADVISORY, Member | 2017 - Present |
Teaching Experience
| Medicine, Course, Course Director, Radiobiology for Radiation Oncology Residents | Annual 2023-present |
| MSCI740, Medicine, Lecture, Lecturer, Master of Science in Clinical Investigation (MSCI 740) course | Summer 2023-present |
| Medicine, Lecture, Lecturer, Mechanisms of Drug Action | Summer 2023-present |
| Pharm 792-4, Medicine, Lecture, Lecturer, PHARM 792 Research in Pharmacology and Toxicology | Annual 2023- |
| SOM614, Medicine, Lecture, Course Presenter, SOM 614 | Fall 2015-present |
| Medicine, Course, Course Presenter, Radiobiology for Radiation Oncology Residents | Annual 2015-2023 - 2023 |
Directed Student Learning
| Supervised Research, Advised: Turner Smith | 2025 - Present |
| Dissertation Defense Committee Member, Advised: Francesca Spirito | 2025 - Present |
| Supervised Research, Advised: John Holly Tacket | 2023 - Present |
| Dissertation Committee Chair, Advised: Imani Kirven | 2023 - Present |
| Dissertation Defense Committee Member, Advised: Elliot Varney | 2019 - 2024 |
| Dissertation Defense Committee Member, Advised: Juliana Sitta | 2018 - 2024 |
| Supervised Research, Advised: Grace Thaggard | 2017 - 2019 |
| Internship Advisor, Advised: Afsana Jahan | 2017 - 2018 |
| Internship Advisor, Advised: Brooke Bell | 2016 - 2023 |
| Internship Advisor, Advised: Litty Thomas | 2015 - 2017 |
Fellows supervised
| CCRI, Post-Doc Advisor, 1 fellows supervised | 01/2015 - 01/2023 |
Residency Training
| Biomedical Imaging & Engineering, Research Advisor | 2019 - 12/2024 |